Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1/2 study of ODM-212 in advanced solid tumors with Hippo pathway alterations
2022-503061-29-00Phase 2Authorised
- Sponsor
- Orion Corporation
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of ODM-212 in Nonhematologic neoplasms (3 arms), sponsored by Orion Corporation. Primary endpoints: Safety and tolerability, Dose selection and 1 more. Planned start Jan 2024; status: authorised.
02
Drugs
ODM-212
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-503061-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503061-29-00.